These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 9215602)

  • 41. Formal total synthesis of fostriecin.
    Wang YG; Kobayashi Y
    Org Lett; 2002 Dec; 4(26):4615-8. PubMed ID: 12489943
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Suppression of Ser/Thr phosphatase 4 (PP4C/PPP4C) mimics a novel post-mitotic action of fostriecin, producing mitotic slippage followed by tetraploid cell death.
    Theobald B; Bonness K; Musiyenko A; Andrews JF; Urban G; Huang X; Dean NM; Honkanen RE
    Mol Cancer Res; 2013 Aug; 11(8):845-55. PubMed ID: 23671329
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Differential actions of aclarubicin and doxorubicin: the role of topoisomerase I.
    Bridewell DJ; Finlay GJ; Baguley BC
    Oncol Res; 1997; 9(10):535-42. PubMed ID: 9507531
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Human DNA topoisomerase IIalpha-dependent DNA cleavage and yeast cell killing by anthracycline analogues.
    Binaschi M; Farinosi R; Austin CA; Fisher LM; Zunino F; Capranico G
    Cancer Res; 1998 May; 58(9):1886-92. PubMed ID: 9581829
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Modification of the antibiotic olivomycin I at the 2'-keto group of the side chain. Novel derivatives, antitumor and topoisomerase I-poisoning activity.
    Tevyashova AN; Olsufyeva EN; Balzarini J; Shtil AA; Dezhenkova LG; Bukhman VM; Zbarsky VB; Preobrazhenskaya MN
    J Antibiot (Tokyo); 2009 Jan; 62(1):37-41. PubMed ID: 19132061
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Alkylator resistance in human B lymphoid cell lines: (2). Increased levels of topoisomerase II expression and function in a melphalan-resistant B-CLL cell line.
    Pu QQ; Bezwoda WR
    Anticancer Res; 2000; 20(4):2569-78. PubMed ID: 10953328
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer.
    Arpino G; Ciocca DR; Weiss H; Allred DC; Daguerre P; Vargas-Roig L; Leuzzi M; Gago F; Elledge R; Mohsin SK
    Breast Cancer Res Treat; 2005 Jul; 92(1):69-75. PubMed ID: 15980993
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Structure-activity studies with cytotoxic anthrapyrazoles.
    Begleiter A; Lin D; Larson KK; Lang J; Wu X; Cabral T; Taylor H; Guziec LJ; Kerr PD; Hasinoff BB; Guziec FS
    Oncol Rep; 2006 Jun; 15(6):1575-80. PubMed ID: 16685398
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Chinese hamster ovary cells resistant to the topoisomerase II catalytic inhibitor ICRF-159: a Tyr49Phe mutation confers high-level resistance to bisdioxopiperazines.
    Sehested M; Wessel I; Jensen LH; Holm B; Oliveri RS; Kenwrick S; Creighton AM; Nitiss JL; Jensen PB
    Cancer Res; 1998 Apr; 58(7):1460-8. PubMed ID: 9537249
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Linker length in podophyllotoxin-acridine conjugates determines potency in vivo and in vitro as well as specificity against MDR cell lines.
    Rothenborg-Jensen L; Hansen HF; Wessel I; Nitiss JL; Schmidt G; Jensen PB; Sehested M; Jensen LH
    Anticancer Drug Des; 2001 Dec; 16(6):305-15. PubMed ID: 12375883
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Sequence-specific potentiation of topoisomerase II inhibitors by the histone deacetylase inhibitor suberoylanilide hydroxamic acid.
    Marchion DC; Bicaku E; Daud AI; Richon V; Sullivan DM; Munster PN
    J Cell Biochem; 2004 May; 92(2):223-37. PubMed ID: 15108350
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Using specific cytotoxics with a targeted mind.
    Di Leo A; Claudino WM; Pestrin M; Licitra S; Biganzoli L
    Breast; 2007 Dec; 16 Suppl 2():S120-6. PubMed ID: 17720501
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effect of pyrazoloacridine (NSC 366140) on DNA topoisomerases I and II.
    Adjei AA; Charron M; Rowinsky EK; Svingen PA; Miller J; Reid JM; Sebolt-Leopold J; Ames MM; Kaufmann SH
    Clin Cancer Res; 1998 Mar; 4(3):683-91. PubMed ID: 9533538
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Versatile enantiocontrolled synthesis of (+)-fostriecin.
    Esumi T; Okamoto N; Hatakeyama S
    Chem Commun (Camb); 2002 Dec; (24):3042-3. PubMed ID: 12536807
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Comparison of the effects of flavone acetic acid, fostriecin, homoharringtonine and tumour necrosis factor alpha on colon 38 tumours in mice.
    Baguley BC; Calveley SB; Crowe KK; Fray LM; O'Rourke SA; Smith GP
    Eur J Cancer Clin Oncol; 1989 Feb; 25(2):263-9. PubMed ID: 2702981
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The predicted beta12-beta13 loop is important for inhibition of PP2Acalpha by the antitumor drug fostriecin.
    Evans DR; Simon JA
    FEBS Lett; 2001 Jun; 498(1):110-5. PubMed ID: 11389908
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Total synthesis of fostriecin (CI-920) via a convergent route.
    Miyashita K; Ikejiri M; Kawasaki H; Maemura S; Imanishi T
    Chem Commun (Camb); 2002 Apr; (7):742-3. PubMed ID: 12119701
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Molecular Targets of Ascochlorin and Its Derivatives for Cancer Therapy.
    Min-Wen JC; Yan-Jiang BC; Mishra S; Dai X; Magae J; Shyh-Chang N; Kumar AP; Sethi G
    Adv Protein Chem Struct Biol; 2017; 108():199-225. PubMed ID: 28427561
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Histopathological changes in dog kidneys following administration of lienomycin].
    Belova IP
    Antibiotiki; 1973 Jul; 18(7):645-50. PubMed ID: 4773829
    [No Abstract]   [Full Text] [Related]  

  • 60. Total and Formal Syntheses of Fostriecin.
    Dong G; Li B; O'Doherty G
    Org Chem Front; 2020 Nov; 7(22):3608-3615. PubMed ID: 33184589
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.